CORT · Corcept Therapeutics Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| patients have now started treatment with Lifyorli following FDA approval in March 2026 | 1,300 | Q2 FY2026 | — |
| hazard ratio (dazucorilant 300 mg vs placebo) | 0.16 | DAZALS Phase 2 study | — |
| increase in the number of tablets sold compared to the prior year | 37% | full year 2025 | — |
| p-value (dazucorilant 300 mg vs placebo) | 0 | DAZALS Phase 2 study | — |
| reduction in risk of death during the study's first year (dazucorilant 300 mg vs placebo) | 84% | DAZALS Phase 2 study | — |
| reduction in risk of death in patients with platinum-resistant ovarian cancer (PROC) | 35% | Phase 3 ROSELLA study | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CORT
this stock
Corcept Therapeutics Inc
|
$12.94B | +242.0% | +12.8% | 284.9 | 9.1% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CORT | +6.1% | +31.0% | +232.6% | +4.0% | +242.0% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +6.5% | +28.1% | +221.1% | +1.0% | +229.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.